|Market Size in 2021||Market Forecast in 2028||CAGR (in %)||Base Year|
|USD 11.01 Billion||USD 14.03 Billion||2.8%||2021|
General Anxiety Disorder Treatment Market
The global General Anxiety Disorder Treatment Market accrued earnings worth approximately 11.01 (USD Billion) in 2021 and is predicted to gain revenue of about 14.03 (USD Billion) by 2028, is set to record a CAGR of nearly 2.8% over the period from 2022 to 2028. The study provides an assessment and analysis of the General Anxiety Disorder Treatment Market on a global & regional level. It offers a comprehensive assessment of the market competition, constraints, revenue estimates, opportunities, evolving trends, and industry-validated data. The report provides historical data from 2018 to 2021 along with a forecast from 2022 to 2028 based on revenue (USD Billion).
General Anxiety Disorder is a mental health ailment producing fear, worry, and a consistent feeling of getting overwhelmed. Apart from this, it features excess, constant, and unrealistic worry about routine activities among individuals. Moreover, the worry can be of health issues, family, and financial matters. According to NCBI, nearly twenty percent of adults suffer from this disorder each year. Reportedly, a general anxiety disorder can have physical as well as emotional effects on a person. An individual suffering from general anxiety disorder possesses unrealistic & exaggerated fears or imaginary fears which are not connected with anything concrete or associated with any such fearsome situation. Moreover, an individual can feel anxious about anything and this is referred to as generalized or general anxiety. It has been found the syndrome or disorder is detected in persons who had suffered from some kind of trauma in childhood, lived through a hard period or suffered losses, and undergo extreme work stress or family problems.
According to NCBI, general anxiety disorder is a common kind of anxiety ailment found both in men and women. Moreover, it is generally found in elderly or middle-aged persons as well as in children. The condition is less common in persons over sixty-five years old. There are different ways of treating this disorder and it includes psychological therapy such as cognitive behavioral treatment, intake of medicines such as anti-depressants, relaxation techniques including meditation, and getting involved in self-help groups.
The massive growth of the general anxiety disorder treatment industry over the next few years can be attributed to rising in work stress & hectic lifestyle. In addition to this, the rise in the production of medicines for treating general anxiety disorder will open new growth dimensions for the general anxiety disorder treatment market. Furthermore, massive use of psychotherapy and treating patients with psychoactive medicines are few of the effective therapeutic solutions for general anxiety disorder. Moreover, the rise in incidences of general anxiety disorders can be attributed to heredity, stressful event, and brain chemistry. A rise in awareness about mental disorders, early diagnosis of these disorders, and awareness among people about the need for treating them immediately will drive market trends. However, the lack of availability of any specific diagnostics tests for determining general anxiety disorder and its treatment can deter the growth of the general anxiety disorder treatment market. Apart from this, nausea and dry mouth are the side effects associated with the intake of medicines and this can pose a barrier to market expansion.
|Report Attributes||Report Details|
|Report Name||General Anxiety Disorder Treatment Market|
|Market Size in 2021||11.01 (USD Billion)|
|Market Forecast in 2028||14.03 (USD Billion)|
|Growth Rate||CAGR of 2.8%|
|Number of Pages||217|
|Key Companies Covered||Pfizer, Inc., Merck & Co. Inc., AstraZeneca, GlaxoSmithKline plc, Eli Lilly and Company, Bristol-Myers Squibb, Johnson & Johnson, and H. Lundbeck A/S|
|Segments Covered||By Drug Class, By Indication, By Distribution Channel, By Region|
|Regions Covered||North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA)|
|Historical Year||2015 to 2020|
|Forecast Year||2022 - 2028|
|Customization Scope||Avail customized purchase options to meet your exact research needs. Request For Customization|
North America General Anxiety Disorder Treatment Market To Witness Exponential Growth By 2028
Regional dominance of North America over forthcoming years can be due to factors such as a rise in cases of general anxiety among the workforce in countries such as the U.S. due to long working hours and hectic & irregular lifestyles. Apart from this, the presence of key players in the sub-continent will contribute sumptuously toward the regional market surge.
Some of the major players have strongly leveraged the growth of the general anxiety disorder treatment market and will continue to do so even in near future. They are Pfizer, Inc., Merck & Co. Inc., AstraZeneca, GlaxoSmithKline plc, Eli Lilly and Company, Bristol-Myers Squibb, Johnson & Johnson, and H. Lundbeck A/S.
The global General Anxiety Disorder Treatment Market is segmented as follows:
Massive growth of general anxiety disorder treatment industry over next few years can be attributed to rise in work stress & hectic lifestyle.
According to Zion market research report, The global General Anxiety Disorder Treatment Market accrued earnings worth approximately 11.01 (USD Billion) in 2021 and is predicted to gain revenue of about 14.03 (USD Billion) by 2028, is set to record a CAGR of nearly 2.8% over the period from 2022 to 2028.
North America will contribute sizably towards the global market revenue over the projected timeline. A massive increase in General Anxiety Disorder Treatment Market size in sub-continent in 2022-2028 can be due to factors such as rise in cases of general anxiety among the workforce in countries such as the U.S. due to long working hours and hectic & irregular lifestyle.
The key industry participants leveraging business space include Pfizer, Inc., Merck & Co. Inc., AstraZeneca, GlaxoSmithKline plc, Eli Lilly and Company, Bristol-Myers Squibb, Johnson & Johnson, and H. Lundbeck A/S.